Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CING
CING
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CING News
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
Jan 23 2026
NASDAQ.COM
Roth Capital Reaffirms Buy Rating on Cingulate, Reduces Price Target to $16
Nov 19 2025
Benzinga
INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading
Oct 24 2025
NASDAQ.COM
Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting
Oct 23 2025
Newsfilter
Roth Capital Reaffirms Buy Rating on Cingulate, Increases Price Target to $17
Oct 15 2025
Benzinga
Cingulate Forms Exclusive Manufacturing Alliance with Bend Bio Sciences for Upcoming ADHD Treatment Commercialization
Sep 17 2025
Newsfilter
Ascendiant Capital Reiterates Buy Rating on Cingulate and Increases Price Target to $62
Aug 22 2025
Benzinga
Cingulate Reports Increased Losses in Q2
Aug 19 2025
NASDAQ.COM
Cingulate Inc. Announces Financial Results for Q2 2025 and Shares Recent Developments
Aug 19 2025
Newsfilter
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
Aug 06 2025
Newsfilter
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
Jul 29 2025
Newsfilter
Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer
May 27 2025
Newsfilter
Ascendiant Capital Maintains Buy on Cingulate, Raises Price Target to $61
May 27 2025
Benzinga
Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD
May 20 2025
NASDAQ.COM
Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $11
May 19 2025
Benzinga
Cingulate Reports Details Of Pre-NDA Minutes For CTx-1301; NDA Submission Planned For Summer
May 14 2025
NASDAQ.COM
Show More News
